Method
Level · gp.fundamentals.capex_revenue_ratio
Raw value 22.34% · OPTIONAL
· Biological Products, (No Diagnostic Substances)
RESEARCH SNAPSHOTDenali Therapeutics Inc.'s latest supported as-filed period reports revenue of $3.6M. Every value below links to its SEC accession and metric lineage.
No material rule-based research observation currently meets GrossPattern's Insight value threshold. Current state, direction, and filing evidence remain available below.
A multidimensional view of the latest comparable filing—not a composite score or recommendation.
Level · gp.fundamentals.capex_revenue_ratio
Raw value 22.34% · OPTIONAL
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
Raw value -2691.51% · OPTIONAL
Level · gp.fundamentals.inventory_revenue_ratio
Raw value 114.84% · OPTIONAL
Level · gp.fundamentals.gross_margin
Raw value 97.42% · CORE
Level · gp.fundamentals.operating_margin
Raw value -3622.11% · CORE
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
Raw value 2691.98% · OPTIONAL
Business direction, financial quality, capital allocation, and governance evidence remain separate—never collapsed into a recommendation score.
Interpretation boundary Direction describes measurable company fundamentals. Governance reports observable evidence only; it does not grade management character or predict stock returns.
Latest available comparable states within 180 days, normalized with robust median/MAD statistics.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
Current assets changed -19.3% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes. This reverses 2 consecutive comparable moves in the opposite direction.
Cash & equivalents changed +42.7% from the comparable as-filed period. The change ranks at the 75th percentile of 4 prior comparable changes.
Each point keeps the date investors could first observe it and its accession.
DNLI · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0002124755-26-000007SEC ↗4Sep 4, 2026Period Sep 2, 20260001797826-26-000006SEC ↗4Sep 3, 2026Period Sep 1, 20260001724311-26-000014SEC ↗4Aug 14, 2026Period Aug 12, 20260001724310-26-000007SEC ↗4Aug 13, 2026Period Aug 11, 20260001724311-26-000013SEC ↗10-QAug 6, 2026Period Jun 30, 20260001714899-26-000097SEC ↗8-KAug 6, 2026Period Aug 6, 20260001714899-26-000096SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Sep 4, 2026Filed Sep 9, 2026 | Chin Peter ScottChief Medical Officer | Open Market SaleDirect | 1,654 | $22 | $36,868 | Form 4 ↗ |
| Sep 2, 2026Filed Sep 4, 2026 | Thornberry NancyDirector | Open Market SaleDirect | 10,824 | $23 | $247,328 | Form 4 ↗ |
| Sep 2, 2026Filed Sep 4, 2026 | Thornberry NancyDirector | Open Market SaleDirect | 615 | $24 | $14,600 | Form 4 ↗ |
| Sep 1, 2026Filed Sep 3, 2026 | Schuth Alexander O.COFO and Secretary | Open Market SaleDirect | 2,768 | $23 | $64,882 | Form 4 ↗ |
| Aug 12, 2026 |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Level · gp.fundamentals.sbc_revenue_ratio
Raw value 635.82% · OPTIONAL
Operating cash flow changed -28.8% from the comparable as-filed period.
Free-cash-flow proxy changed -22.9% from the comparable as-filed period.
Shares outstanding changed +9.3% from the comparable as-filed period. The change ranks at the 88th percentile of 8 prior comparable changes.
Capital expenditure changed -81.2% from the comparable as-filed period.
Working capital changed -21.3% from the comparable as-filed period. The change ranks at the 50th percentile of 4 prior comparable changes. This reverses 2 consecutive comparable moves in the opposite direction.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001714899-26-000086| Watts Ryan J.President and CEO |
| GiftIndirect |
| 32,220 |
| $0 |
| $0 |
| Form 4 ↗ |